United States · 
Who invested in Code Biotherapeutics?
Code Biotherapeutics's investors include New Enterprise Associates, Hatteras Venture Partners and Northpond Ventures.
United States · Series A startup
Who invested in Code Biotherapeutics
Funding summaryUpdated 26 Oct 2026
$75Mraised across 1 round since 2022, from 1 source
- Latest round
- Series A, $75MJun 2022
- Investors
- 3
The rounds
- Jun 2022Series A$75M
Source recordedSEC filing: $37M sold, first sale May 2022
Founders and team
From the SEC filings it signed: 5 on the team.
- Brian McVeighExecutive Officer, Directori
- Erin C BrubakerExecutive Officeri
- Lauren C KaskielExecutive Officeri
- Robert C GettsExecutive Officeri
- Russ FeinExecutive Officer, Directori
On the board, as filediDmitry KuzminEdward MathersJoseph TruittKathy RouanRobert LinVictor Stone
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Code Biotherapeutics
How much has Code Biotherapeutics raised?
Code Biotherapeutics has raised $75M across 1 round since 2022.
When did Code Biotherapeutics last raise?
Code Biotherapeutics's most recent round was a Series A of $75M in Jun 2022.
What was Code Biotherapeutics's biggest round?
Its most recent round, $75M in Jun 2022, is also its largest on record.
Who backed Code Biotherapeutics first?
Code Biotherapeutics's first round on record, in Jun 2022, was backed by New Enterprise Associates, Hatteras Venture Partners and Northpond Ventures.
What stage is Code Biotherapeutics at?
Code Biotherapeutics's latest named round is a Series A, in Jun 2022.
Where is Code Biotherapeutics based?
Code Biotherapeutics is based in the United States.
Companies like Code Biotherapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.